Source: Lieyun Network
Recently, BioGeometry announced the completion of its Pre-A round of financing, led by Techbeing Ventures, with participation from Zhipu AI and SJ Jiacheng Investment Management Co. Ltd. Existing shareholder Gaorong Ventures continued to increase its investment. The funds from this round will mainly be used to accelerate the implementation of generative AI large models in the biomanufacturing field, as well as to advance the development of proprietary products.
BioGeometry is a generative AI protein design platform provider dedicated to developing next-generation artificial intelligence technologies such as geometric deep learning and deep generative models for large molecule drug research and development. The company is building two foundational platforms: an AI-driven large molecule drug design platform and a high-throughput large molecule drug wet-lab validation platform. Through a closed-loop integration of computational ("dry") and experimental ("wet") processes, the company aims to rapidly design candidate drugs and improve their success rate during clinical stages. BioGeometry has also launched TorchProtein, an open-source machine learning platform for large molecule drug discovery, which seeks to accelerate the drug development process through AI.
According to its official website, the company was founded in 2022 by Dr. Jian Tang, a top scientist in AI drug discovery, with Yoshua Bengio, the father of deep learning and Turing Award winner, serving as the chief scientific advisor. Currently, the company has built two fundamental platforms: the AI large-molecule drug design platform (GeoBiologics) and a high-throughput large-molecule drug wet-lab validation platform, achieving a closed-loop integration of dry and wet experiments. These platforms are empowering partners to achieve precise and efficient large-molecule drug design and optimization.